AllSci News
Amgen’s tarlatamab delivers Phase III OS win in first-line ES-SCLC maintenance
Adding tarlatamab to durvalumab maintenance produced a statistically significant and clinically meaningful improvement in overall survival in...
Moonwalk Bio raises USD 70m Series B for adipose-targeted obesity therapies
South San Francisco-based Moonwalk Biosciences has closed an oversubscribed USD 70 million Series B financing to advance a pipeline of adipose-targeted RNA...
AZ’s tozorakimab shows Phase III benefit across eosinophil levels in COPD
Full Phase III results from the previously announced positive OBERON and TITANIA trials show that AstraZeneca's IL-33 antibody tozorakimab reduced...
FDA approves AZ’s Etcamah for pre-progression switch in HR+ breast cancer
AstraZeneca has received accelerated approval from the US FDA for Etcamah (camizestrant), an oral selective estrogen receptor degrader (SERD), in...
Novartis’s pelacarsen misses Phase III endpoint despite deep Lp(a) lowering
Novartis’s pelacarsen failed to reduce major cardiovascular events in the Phase III Lp(a)HORIZON trial despite substantially lowering lipoprotein(a)...
Novartis’s Avidity-acquired del-desiran falls short in Phase III DM1 trial
The Phase III HARBOR study of delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 (DM1) has failed its primary endpoint, dealing a major...
BrainChild Bio raises USD 116m to advance CAR T therapy for pediatric brain cancer
Seattle-based BrainChild Bio, Inc., a clinical-stage company developing CAR T cell therapies for central nervous system tumors, has closed a USD 116 million...
Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch
Massachusetts-based Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced a non-dilutive senior secured term loan facility of up to USD 400 million with...
Acepodia wins FDA clearance for dual-payload GPC3 ADC in liver cancer
California- and Taiwan-based Acepodia (TWSE: 6976) has received US FDA clearance to begin Phase I testing of ACE723, a GPC3-targeted dual-payload...
NeuShen lands USD 80m+ Series B for CNS expansion
With three central nervous system (central nervous system, or CNS) clinical-stage programs under way up to Phase II, China-based NeuShen Therapeutics...
Argo's siRNA therapy cuts HAE attack rates 83–96% in small Phase II study
&x20;Argo Biopharmaceutical Co., Ltd. (Argo Biopharma) provided updated Phase II data for BW-20805, an investigational small interfering RNA (siRNA) therapy...
Stoke, Biogen report four-year durability for Dravet therapy zorevunersen
Four-year open-label extension data for zorevunersen, the antisense oligonucleotide being developed by Massachusetts-based Stoke Therapeutics (Nasdaq: STOK)...
Innovent takes once-weekly oral GLP-1 into Phase I
Innovent Biologics (HKEX: 01801) has registered a Phase I study of IBI3042, an oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist...
Dimerix secures AUD 34m non-dilutive funding through Phase III kidney disease trial readout
Australia-based Dimerix Limited (ASX: DXB) announced a non-dilutive loan facility of AUD 34 million (USD 23.9 million) with a syndicate of Australian and US...
FDA requests public input on botanical drug product development pathways
The FDA has issued a Request for Information (RFI) seeking public comment on how to advance the development of FDA botanical drug products — therapeutics...
The AllSci Brief
Free, systematic R&D and deal news. Daily.